Brexpiprazole vs. Sertraline: PTSD Treatment Options for PI Cases

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 8 min read

Brexpiprazole (Rexulti) and sertraline (Zoloft) represent different pharmacological approaches to PTSD in personal injury patients. This comparison explains their mechanisms, FDA status, and what each signals on a pharmacy lien.

Sertraline is an FDA-approved first-line SSRI for post-traumatic stress disorder, while brexpiprazole is an atypical antipsychotic that received FDA approval in 2024 specifically as an adjunct for PTSD. When both or either appears in a personal injury pharmacy lien record, it indicates the treating provider has formally diagnosed PTSD and is managing it with evidence-based pharmacotherapy rather than relying solely on analgesics or anxiolytics.

• Sertraline (Zoloft) is one of only two FDA-approved medications for PTSD (along with paroxetine) and is the standard first-line pharmacotherapy
• Brexpiprazole (Rexulti) received FDA approval in 2024 for adjunctive treatment of PTSD, making it the first new PTSD-specific approval in over two decades
• Sertraline is a generic SSRI; brexpiprazole is a branded atypical antipsychotic with a different cost and formulary profile
• The presence of brexpiprazole specifically signals treatment-resistant or severe PTSD requiring augmentation beyond SSRI monotherapy
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report that documents the clinical rationale for PTSD pharmacotherapy in the context of the injury

Mechanism of Action

Sertraline selectively inhibits serotonin reuptake at the presynaptic terminal, increasing serotonin availability in the synaptic cleft. In PTSD, serotonergic deficiency contributes to hyperarousal, re-experiencing symptoms, emotional numbing, and avoidance behaviors. By restoring serotonin signaling, sertraline addresses the core neurochemical disruption underlying PTSD symptomatology.

Brexpiprazole is a serotonin-dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A receptors. This multi-receptor profile allows it to modulate both serotonergic and dopaminergic tone without the full receptor blockade associated with traditional antipsychotics. In PTSD, this mechanism addresses the hyperarousal, irritability, and affective dysregulation that may persist despite adequate SSRI therapy.

Side-by-Side Comparison

Clinical Significance for Personal Injury

PTSD is one of the most common psychiatric sequelae of personal injury events. Motor vehicle accidents, assaults, pedestrian collisions, and other traumatic incidents frequently produce PTSD that persists long after physical injuries have healed. The presence of PTSD pharmacotherapy in the pharmacy record is clinically significant because it documents an additional injury dimension beyond physical damage.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "Sertraline appearing on a PI pharmacy lien confirms a PTSD diagnosis that adds meaningful case value. When we also see brexpiprazole added to the regimen, it tells us the PTSD is severe enough to require augmentation therapy, which further strengthens the documentation of psychological injury."

Sertraline as monotherapy is the expected starting point. When a patient responds adequately to sertraline alone, the pharmacy record shows a single PTSD agent maintained at a stable dose. However, many PI patients with severe trauma do not achieve full remission on SSRI monotherapy. The addition of brexpiprazole to sertraline in the pharmacy record documents a clinical escalation that directly correlates with PTSD severity and treatment complexity.

Prescribing Patterns in PI Context

Typical PTSD pharmacotherapy progression in PI cases follows a recognizable pattern:

1. Initial SSRI trial — Sertraline 50 mg titrated to 100-200 mg over 4-8 weeks
2. Assessment of response — If partial response at maximum tolerated dose for adequate duration
3. Augmentation decision — Addition of brexpiprazole or switch to alternative SSRI/SNRI
4. Combination therapy — Sertraline plus brexpiprazole for treatment-resistant cases

This stepwise approach is consistent with clinical practice guidelines and demonstrates that the prescriber followed an appropriate treatment algorithm before adding a second agent.

Settlement and Documentation Impact

The pharmacy lien record of PTSD medication progression provides powerful settlement documentation. A patient on sertraline alone has documented PTSD. A patient on sertraline plus brexpiprazole has documented treatment-resistant PTSD requiring combination pharmacotherapy. The latter case demonstrates a more severe and persistent psychological injury that is likely to affect the patient's quality of life and functioning for an extended period.

Defense counsel may challenge PTSD medication claims by arguing symptoms are pre-existing or unrelated to the accident. The pharmacy record's timeline is critical: if sertraline was initiated within weeks of the accident and brexpiprazole was added months later as symptoms persisted despite adequate SSRI therapy, the causal connection to the traumatic event is well-documented through the dispensing history.

Safety and Monitoring

Both medications have distinct monitoring requirements that appear in the clinical record:

Sertraline is generally well-tolerated with a favorable safety profile. Common side effects include GI disturbance (nausea, diarrhea), sexual dysfunction, and initial activation/insomnia. Serotonin syndrome is a rare risk when combined with other serotonergic agents.

Brexpiprazole requires metabolic monitoring (weight, glucose, lipids) due to the class effect of atypical antipsychotics on metabolic parameters. Akathisia (motor restlessness) is a notable side effect that may be confused with anxiety symptoms. Long-term use carries a theoretical risk of tardive dyskinesia, though the risk with brexpiprazole is considered lower than with older antipsychotics.

Related Resources

• PTSD Medication Management in Personal Injury
• Sertraline vs. Venlafaxine for PTSD and Anxiety
• Rexulti, PTSD, and Sleep Medications in PI
• Depression After Injury: Medications and Pharmacy Liens